Biotechnology company BioMarin Pharmaceutical Inc (Nasdaq:BMRN) said on Friday that it has earned a USD15m in milestone payment from Pfizer Inc following European Commission (EC) approval of TALZENNA (talazoparib) for the treatment of adult patients with metastatic breast cancer (MBC).
The European Commission EC has approved TALZENNA (talazoparib) for the treatment of adult patients with germline breast cancer susceptibility gene (gBRCA) 1/2-mutations, who have human epidermal growth factor receptor 2-negative (HER2-) locally advanced (LA) or metastatic breast cancer (MBC).
Earlier in 2015, Medivation Inc and BioMarin Pharmaceutical Inc launched an asset purchase agreement, under which Medivation acquired all worldwide rights to talazoparib, a once-daily, oral poly (ADP-ribose) polymerase (PARP) inhibitor. Medivation was later acquired by Pfizer in September 2016.
In conjunction with the agreement, Medivation paid BioMarin USD410m upfront and BioMarin is entitled to receive up to an additional USD160m (in aggregate) upon the achievement of regulatory and sales-based milestones, of which USD50m has been earned to date, as well as mid-single digit royalties for talazoparib.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML